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Routine care of peripheral intravenous catheters versus
clinically indicated replacement: randomised controlled trial
Joan Webster, nursing director, research; adjunct professor,1,2 Samantha Clarke, clinical nurse,1
Dana Paterson, research nurse,1 Anne Hutton, clinical nurse,1 Stacey van Dyk, research nurse,1
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ABSTRACT
Objective To compare routine replacement of intravenous
peripheral catheterswith replacementonlywhenclinically
indicated.
Design Randomised controlled trial.
Setting Tertiary hospital in Australia.
Participants 755 medical and surgical patients: 379
allocated to catheter replacement only when clinically
indicated and 376 allocated to routine care of catheter
(control group).
Main outcomemeasure A composite measure of catheter
failure resulting from phlebitis or infiltration.
Results Catheters were removed because of phlebitis or
infiltration from 123 of 376 (33%) patients in the control
group compared with 143 of 379 (38%) patients in the
intervention group; the difference was not significant
(relative risk 1.15, 95% confidence interval 0.95 to 1.40).
When the analysis was based on failure per 1000 device
days (number of failures divided by number of days
catheterised, divided by 1000), no difference could be
detected between the groups (relative risk 0.98, 0.78 to
1.24). Infusion related costs were higher in the control
group (mean $A41.02; £19.71; €24.80; $38.55) than
intervention group ($A36.40). The rate of phlebitis in both
groups was low (4% in intervention group, 3% in control
group).
Conclusion Replacing peripheral intravenous catheters
when clinically indicated has no effect on the incidence of
failure, based on a composite measure of phlebitis or
infiltration. Larger trials are needed to test this finding
using phlebitis alone as a more clinically meaningful
outcome.
Registration number Australian New Zealand Clinical
Trials Registry ACTRN12605000147684.
INTRODUCTION
Intravenous catheterisation is the most common
invasive procedure among patients admitted to hospi-
tal, with about half receiving intravenous therapy
during their stay.1 The procedure is not without risks.
Between 2.3% and 67% of patients develop throm-
bophlebitis; the rate dependingondefinitions used and
populations studied.2-8 Themore serious complication,
infection of the bloodstream, occurs in about 0.1% of
cases.9
Many interventions have been developed to reduce
the incidence of phlebitis, including new catheter
materials,10 11 innovative methods for securing the
catheter,12 13 and heparinised catheters.14 The most
widely practised intervention, however, is routine
replacement of the catheter. The Centers for Disease
Control and Prevention advocate replacing catheters
every 72-96 hours to limit the potential for infection,15
but the recommendation is based on scant evidence.16
More recent observational studies indicate that cathe-
ters may be safely left in place for longer periods.1 7 11 17
Some evidence also suggests that phlebitis is more
likely to occur in the twodays after catheterisation.1 17 18
Consequently, removing a functional catheter and re-
siting it might expose patients to unnecessary risk.
Despite the ubiquitous use of peripheral intravenous
catheters and the almost universal acceptance of the
need for routine replacement, the practice has received
little rigorous evaluation. We found a total of four
randomised controlled trials comparing some form of
routine catheter replacement with peripheral venous
infusion. Two of these trials were small, carried out in a
gastroenterology unit of Scarborough Hospital in the
United Kingdom, and enrolled patients only receiving
total parenteral nutrition through a peripheral venous
catheter.19 20 Because of the uniqueness of this group,
results are not relevant to the current discussion. The
third study was carried out in the same unit of the
ScarboroughHospital.21 Itwas the first trial to compare
outcomes between groups in a general hospital
population where the peripheral catheter was either
routinely replaced or changed only when clinically
indicated. In the control group (n=26), peripheral
venous catheters were replaced every 48 hours and in
the intervention group removed “if the site became
painful, the cannula dislodged or there were signs of
peripheral vein thrombosis” (n=21). Phlebitis occurred
in 1 (5%) patient in the control group and 11 (42%) in
the intervention group. The study was criticised for its
small sample size (sample size and power estimates
were not reported) and the involvement of the chief
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investigator in both the randomisation process and the
outcome assessment.22 Moreover, the incidence of
phlebitis in the intervention group was much higher
than contemporary rates.
We recognised the need to test current standards
using an appropriately powered randomised con-
trolled trial. In March 2004 we began a study using a
small sample to compare the safety and efficacy of
replacing intravenous catheters after three days with
only when clinically indicated.23 Challenging the
guidelines from the Centers for Disease Control and
Prevention made the trial controversial and so we
limitedour sample topatients inwhomthe catheterhad
been insertedby the intravenous therapy team; a group
of nurses with extensive collective experience and
expertise in the area. Also we excluded patients who
were immunocompromised, had a current blood-
stream infection, or were unable to sign consent. We
randomised participants into two groups (routine care
of the catheter or replacing the catheter only when
clinically indicated) and used a composite measure of
any unplanned reason for removal of the catheter as
our primary outcome, including phlebitis, blockage, or
infiltration. The secondary outcome was cost. Among
the 206 participants studied we found no significant
differences between groups on the primary outcome.
The duration of peripheral catherisation was similar in
both groups (mean 123.3 hours in the intervention
group, mean 125.9 hours in the control group) but
significantly more re-siting occurred in the control
group (166 resites in the intervention group, 216 resites
in the control group). Three cases of phlebitis occurred
(one in the intervention group, two in the control
group).
As a follow-up to this study we carried out a
randomised trial to compare routine changes of
catheters with clinically indicated changes among a
broader group of acute patients admitted to hospital.
We used a pragmatic design that excluded few patients
and that was carried out under routine hospital
procedures. We tested the safety and efficacy of the
process on a wider population.
METHODS
We recruited inpatients from a general tertiary referral
teaching hospital (982 beds) with several specialties,
includingmedicine, surgery, orthopaedics, psychiatry,
oncology, obstetrics, gynaecology, and trauma ser-
vices. The hospital is the largest in Queensland,
Australia, and provides services to patients throughout
the state, northern New South Wales, the Northern
Territory, and from neighbouring countries in the
southwest Pacific. Patients were eligible for inclusion if
they were at least 18 years of age, had no current
bacteraemia, were not receiving immunosuppressive
therapy, and were scheduled or expected to have a
peripheral venous catheter for at least four days. As the
patient was the unit of measurement for the study we
entered patients requiring multiple or consecutive
catheters into the studyonce only. In the earlier trialwe
had to exclude many, otherwise eligible, participants
because an altered mental state prevented them from
giving informed consent. For the current trial we
sought permission from the hospitals’ human research
ethics committee for the next of kin to sign for patients
who were unable to consent themselves.
Intervention, allocation concealment, and masking
We randomised patients either to routine care (control
group), with catheters scheduled to be replaced every
three days according to hospital policy, or to a group
where the peripheral intravenous catheter was not
replaced unless there was a clinical indication (clini-
cally indicatedgroup). Irrespective of the assignment, a
decision to change a catheter at any time because of
clinical indications such as phlebitis, infiltration, or
unexplained fever could be implemented. We
recorded the reason for replacement of catheters and
deviations from the catheter replacement protocol for
each group.
Block randomisation was by a computer generated
random number list prepared by an investigator with
no clinical involvement in the trial. We stratified by
admission for an oncology related procedure.After the
research nurse had obtained the patient’s consent, she
telephoned a contact who was independent of the
recruitment process for allocation consignment.
Allocation concealment avoided selection bias but
clinical staff were subsequently aware of the treatment
group. This was necessary to ensure that catheters
scheduled for routine replacement were changed and
that those in the clinically indicated group were not
removed if the catheterwas functional and therewasno
sign of local inflammation or infection. Research staff
had no involvement in nominating the reason for
Potentially eligible participants (n=1620)
Reasons for exclusion (n=865):
 Did not want to participate (n=159)
 Altered mental state (n=393)
 Too ill (n=190)
 Language barrier (n=123)
Randomised (n=755)
Allocated to intervention group (n=379)
Received allocated intervention (n=357)
Routinely changed (n=22)
Allocated to control group (n=376)
Received allocated intervention (n=376)
Number completing trial (n=379)
Number analysed (n=379)
Number completing trial (n=376)
Number analysed (n=376)
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catheter removal or in diagnosing phlebitis. Staff in the
microbiological laboratory were blind to group assign-
ment of catheters submitted for testing.
Procedures
After consent and randomisation the research nurse
collected baseline personal, clinical, and catheter
related data, which included the type of infusate and
any additives, drugs injected into the intravenous set
and their pH level, type and size of catheter used, and
the site of insertion. Choice of catheter type and gauge
was at the discretion of the nurse or doctor inserting the
catheter. Catheter insertion sites were inspected daily
by a nurse from the intravenous therapy team and by
ward nurses when intravenous solutions were changed
orwhen drugswere added. Because research staff were
not responsible for recording the reason for catheter
removal, a specially designed form was developed for
completion by the nurse removing the cannula. This
was to optimise the standardisation of reporting
outcome measures.
Any deviations from the protocol were recorded (if
the catheter was replaced at a time other than indicated
by the allocated group).We collected data for up to five
consecutive catheters for each patient.
Outcome measures
For theprimaryoutcomeweused a compositemeasure
of catheter failure as a result of phlebitis or infiltration.
Phlebitis was defined as the presence of two or more of
pain, tenderness, warmth, erythema, swelling, or a
palpable cord.1-25 Infiltration was defined as
permeation of intravenous fluid into the interstitial
compartment, causing swelling of the tissue around the
site of the catheter.
We used several secondary outcomes including
infusion related cost, which was calculated in two
ways—costs associated with catheters inserted for the
intermittent administration of intravenous drugs, and
cost associated with catheters inserted for continuous
infusion. For patients receiving intermittent drugs
(estimated to be 52% of the population on the basis of
data from the earlier trial) we calculated a total cost of
$A16.4. This included 20minutes nursing per medical
time (locating patient, preparation, and insertion), a
catheter, a three way tap, a basic dressing pack, gloves,
a syringe, transparent adhesive dressing, skin disinfec-
tion, and local anaesthetic per insertion. For patients
receiving a continuous infusion we calculated a total
cost of $A28.84per insertion.This included the costs of
the initial cathether set plus the cost of replacing
associated lines, solutions, and additives, which are
discarded when a catheter is replaced (intravenous
administration set, 1 litre sodium chloride 0.09%). We
also included other reasons for catheter failure as
secondary outcomes: occlusion or blockage, local
infection at the insertion site (defined as erythema
with cellulitis at the site or pus at the site), or catheter
related bloodstream infection (on the basis of the
isolation of a phenotypically identical organism from a
catheter segment and a blood culture).11 We also
included phlebitis and infiltration as independent
secondary outcomes.
Statistical analysis
We based our sample size on the combined incidence
of phlebitis and infiltration in controls from our earlier
study (33.5%).23 To detect a difference of at least 30%
betweengroupswitha twosided test,αof 0.05, and90%
power we determined that we needed about 380
patients in each arm.
Trial data were entered using SPSS version 15 and
analysed on an intention to treat basis (all randomised
patients were analysed in the assigned groups). A
validity check was undertaken on a random sample of
5% of the data. We compared baseline clinical and
personal characteristics to test adequacy of the
randomisation process. We calculated the relative
risks and 95% confidence intervals for the proportion
of patients with a failed catheter and for the individual
factors that made up the composite measure. We also
calculated the failure rate for each group per 1000
device days, which is a more meaningful measure for
this outcome, by dividing the total number of catheter
failures by the total number of days catheterised,
multiplied by 1000. When appropriate, we used a two
sided Fisher’s exact test to compare discrete data;
results are presented as P values. We used the
independent sample t test to compare the differences
in the infusion related costs and total catherisation time
between the groups. The guidelines for the consoli-
dated standardsof reporting trials26were followed from
the point of recruitment.
Table 1 | Baseline personal, clinical, and catheter related details of patients allocated to routine
care of intravenous catheter (control group) or to replacement of catheter onlywhen clinically
indicated (intervention group). Values are numbers (percentages) of patients unless stated
otherwise
Variable
Intervention group
(n=379) Control group (n=376)†
Mean (SD) age (years) 60.1 (17.1) 58.8 (18.8)
Male 248 (65) 233 (62)
Type of admission:
Medical 238 (63) 214 (57)
Surgical 141 (37) 162 (43)
>1 comorbidity 280 (74) 270 (72)
Oncology related condition 55 (15) 56 (15)
Current wound infection (including ulcers) 100 (26) 70 (19)
History of phlebitis 13 (3) 4 (1)
Indwelling urinary catheter 63 (17) 79 (21)
Wound drain 72 (19) 43 (11)
Mean (SD) haemoglobin level on admission 126.4 (23.7) 124.5 (23.5)
Skin turger fair or poor 233 (62) 228 (61)
High risk of acquiring nosocomial infection 36 (10) 30 (8)
Poor veins 127 (34) 143 (38)
Catheter inserted by:
Intravenous team 502 (74) 563 (74)
Medical officer 66 (10) 58 (8)
Other nurse (not intravenous team) 113 (17) 140 (18)
Person inserting catheter was unknown in 14 instances.
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RESULTS
Between February 2006 and June 2007, 755 of 1620
potentially eligible participants (46.6%) were included
in the trial. Almost one quarter of potentially eligible
patients were excluded because of an altered mental
state.Thesewere generallypatientswhowere confused
or had some formof dementia or delirium.Reasons for
exclusion are shown in the figure.
Of those recruited, 376 were randomised to routine
care of catheters (control group) and 379 to replace-
ment of catheters only when clinically indicated
(intervention group). Twenty two participants (6%) in
the intervention group had their catheter changed
routinely rather than in response to a clinical indica-
tion. One hundred and twenty five participants (33%)
in the control group had a catheter in place for more
than 72 hours, reflecting the variation in routine care.
Follow-up from medical records was possible for all
participants.
Baseline personal, clinical, and catheter related
characteristics were similar between the groups for
most risk factors (table 1). The exceptions were a
history of phlebitis and presence of a wound infection
or infected ulcer, with higher rates in the intervention
group.
Each catheter was in place for a greater mean length
of time in the intervention group than in the control
group (table 2). As a result more catheters were placed
in the control group (n=749) than in the intervention
group (n=679), despite the average number of intra-
venous therapy days being less in the control group (t=
−2.77,P=0.007; twosided t test): 6.3 (SD5.1)days in the
intervention group and 5.4 (SD 3.8) days in the control
group. The total number of days catheterised were
2020 in the control group and 2393 in the intervention
group.
Effect of intervention
Table 3 shows rates for the primary and secondary
outcomes. Overall, 123 (33%) participants in the
control group and 143 (38%) in the intervention
group had catheters removed as a result of phlebitis
or infiltration; the difference was not significant
(relative risk 1.15, 95% confidence interval 0.95 to
1.40). When the analysis was based on catheter failure
per 1000 device hours, no difference could be detected
between the groups. Infusion related costs were higher
in the control group per episode of care than in the
intervention group (mean $A41.02 v mean $A36.40).
Both groups had a low rate of phlebitis (4% in
intervention group, 3% in control group). Infiltration
was the most common reason for failure (36% in
intervention group, 32% in control group). A total of
196 (26%) catheters in control participants were
replaced after three days, according to hospital policy,
despite functioning well.
DISCUSSION
The routine replacement of peripheral intravenous
catheters has no effect on the incidence of catheter
failure, on the basis of a compositemeasure of phlebitis
or infiltration. The result replicates findings from our
earlier study, which used narrower inclusion criteria
but a broader definition of failure.23 These two studies
have increasedour confidence in changing intravenous
lines according to clinical signs and symptoms, rather
than using predetermined time frames.15Changing our
policy would bring the practice in adults in line with
recommendations from the Centers for Disease Con-
trol and Prevention for changing peripheral intra-
venous lines in children—that is, to replace catheters
only when clinically indicated. Paradoxically, in our
hospital peripheral intravenous lines are not routinely
changed in premature infants or certain other patients
in whom achieving and maintaining venous access is
difficult. Suchpopulations are arguably at higher riskof
developingcatheter related complications thangeneral
medical and surgical patients inwhom routine changes
are mandated.
Our overall combined rate for phlebitis and infiltra-
tionwas 35%, similar to other reports.27 28 The phlebitis
rate in both groups was on the low side of ranges
reported in recent studies,29 30 despite our population
Table 2 | Mean (SD) lengthof timeeachcatheter remained inplace inpatientsallocated to routine
care of intravenous catheter (control group) or to replacement of catheter onlywhen clinically
indicated (intervention group)
Group No Mean (SD) Mean difference (95% CI) P value*
Control 372 66.5 (28.1)
−24.12 (−130.53 to −17.71) <0.000
Intervention 379 90.6 (56.5)
Control 190 59.7 (30.6)
−14.98 (−23.94 to −6.01) 0.001
Intervention 161 74.7 (53.3)
Control 102 55.7 (28.1)
−17.49 (−30.24 to −4.74) 0.007
Intervention 82 57.3 (73.2)
Control 52 60.4 (34.7)
−26.74 (−50.22 to −3.26) 0.026
Intervention 34 87.1 (73.7)
Control 33 57.6 (33.8)
−3.67 (−25.81 to 18.47) 0.741
Intervention 23 61.2 (49.0)
*Two sided t test.
Table 3 | Outcomesforpatientsallocatedtoroutinecareof intravenouscatheter (controlgroup)or
toreplacementofcatheteronlywhenclinicallyindicated(interventiongroup).Valuesarenumbers
(percentages) of patients unless stated otherwise
Outcomes
Intervention group
(n=379) Control group (n=376) Relative risk (95% CI)
Primary:
Catheter failure per
person
143 (38) 123 (33) 1.15 (0.95 to 1.40)
Catheter failure per 1000
device days
59.8 60.9
Secondary:
Mean (SD) intravenous
cost per catheter
41.05 (26.6) 46.22 (28.7) −5.16* (−9.12 to −1.21)
Phlebitis 16 (4) 12 (3) 1.32 (0.63 to 2.76)
Infiltration 135 (36) 120 (32) 1.12 (0.91 to 1.36)
Blockage 30 (8) 20 (5) 1.49 (0.86 to 2.57)
Local infection 2 (1) 0 4.96 (0.24 to 102.98)
Suspected bloodstream
infection
1 (0.3) 1 (0.3) 0.99 (0.06 to 15.80)
*Mean difference.
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being elderly and unwell, with almost 75% having at
least one comorbidity. Reported rates depend on
definitions used, and although we applied a standard
definition, interpretation of signs and symptoms could
still be affectedby subjectivity oromissionof reporting.
For example, it hasbeenargued that infiltration (easy to
diagnose) may result from unrecognised phlebitic
changes to the vein wall (hard to diagnose) leading to
under-reporting of phlebitis.27 It is perhapsmore useful
to use the compositemeasure of infiltration or phlebitis
as it avoids any potential for misdiagnosis.
Despite allocation to the control or intervention
group, participants showed little difference in dwell
times. Two factors contribute to this. Firstly, it is not
possible to modify all routinely scheduled changes
precisely 72 hours after insertion—for example, some
catheters may be left to the next morning rather than
waking apatient during thenight. Secondly, for various
reasonsmany of the catheters in the intervention group
failed before 72 hours—although catheters in the
intervention group remained in place longer than
those in the control group, the average dwell time was
within the 72-96 hours recommended by the Centers
forDiseaseControl and Prevention. This confirms that
all catheters fail eventually but that many remain
functional for prolonged periods.We found that about
3%remained trouble free for over sevendays and some
for as long as twoweeks. Because of this we believe that
routinely changing catheters may be an unnecessary
and painful intervention for patients, and costly for the
organisation.
Potential cost savings of about 25% for infusion
related costs could be made if our policy was to be
changed in line with recent evidence. Cost estimates
used in our studywere conservative, based on a simple
intravenous event. Others have suggested that about
2.5% of total drug costs are wasted when preparations
are destroyed.31 On the basis of recent data from
England this could translate to a cost saving of about
£61m per annum.32
The study was not sufficiently powered to show
differences inour secondary clinical outcomes.Despite
this, non-significant results favoured the control group
for lower rates of phlebitis, blockage, and local
infection. Numbers were small for these outcomes
and confidence intervals wide but with a larger
enrolment this risk could reach statistical significance.
A large, multicentre trial is needed to confirm our
results, using phlebitis or bloodstream infection as the
primary outcome. Several serious adverse events were
reported during the trial. None of these were related to
trial procedures.
Strengths and limitations
The major strengths of the study were the processes
used to eliminate selection bias, to ensure allocation
concealment, and to ensure that the study was
adequately powered to detect differences in our
primary outcome. We also included a broad range of
participants and did not impose any caveats on how or
by whom catheters should be inserted. This was to
match normal clinical practice and to ensure that
results could be extrapolated to other populations of
complex inpatients. We were able to enrol 47% of
potentially eligible patients compared with about 25%
in the earlier trial. Most of those we were unable to
recruit were either too frail or their mental state
prevented them from providing informed consent.
From thepoint of randomisation, no losses to follow-up
occurred.
The studywould have been strengthened ifmonitor-
ing of outcomes had beenmore stringent. As it was, we
extracted most of the outcome data from medical
records. A more standardised approach would have
been preferable, using staff trained in the process and
data collected in real time.Another potential limitation
was that outcome assessment was done by people who
were not blinded to group allocation. Although
catheters were removed by ward staff or intravenous
service staff, part of their normal practice is to record
reasons for removal in the patient’smedical record. To
falsify such an observation because of group allocation
would be unlikely, so we believe our results have not
been compromised. Finally, the studywasnot powered
to study differences in the secondary outcomes.
Phlebitis alone would have been a more clinically
important endpoint butwewere limitedby restrictions
on funding. For the same reason we did not culture
catheter tips. This may have provided additional
information to inform practice and future studies.
Conclusion
Replacing peripheral intravenous catheters only when
clinically indicated does not reduce the incidence of
catheter failure, on the basis of a composite measure of
phlebitis or infiltration. Larger trials are needed to test
this finding using phlebitis alone as a more clinically
meaningful outcome.
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